News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
329,360 Results
Type
Article (19747)
Company Profile (144)
Press Release (309469)
Section
Business (105440)
Career Advice (904)
Deals (18550)
Drug Delivery (91)
Drug Development (50682)
Employer Resources (79)
FDA (7646)
Job Trends (7738)
News (185902)
Policy (17345)
Tag
Academia (738)
Alliances (27769)
Alzheimer's disease (575)
Approvals (7619)
Artificial intelligence (86)
Bankruptcy (170)
Best Places to Work (5538)
Biosimilars (68)
Biotechnology (68)
Breast cancer (75)
Cancer (663)
Cardiovascular disease (66)
Career advice (736)
Cell therapy (102)
Clinical research (41942)
Collaboration (248)
Compensation (83)
COVID-19 (1080)
C-suite (66)
Data (746)
Diabetes (99)
Diagnostics (1732)
Drug pricing (96)
Earnings (38337)
Employer resources (73)
Events (47895)
Executive appointments (230)
FDA (7948)
Funding (178)
Gene therapy (92)
GLP-1 (497)
Government (1812)
Healthcare (5915)
Infectious disease (1130)
Inflammatory bowel disease (71)
Interviews (120)
IPO (7307)
Job creations (2435)
Job search strategy (673)
Layoffs (253)
Legal (4089)
Lung cancer (101)
Manufacturing (138)
Medical device (1977)
Medtech (1980)
Mergers & acquisitions (11304)
Metabolic disorders (343)
Neuroscience (762)
NextGen Class of 2024 (2382)
Non-profit (935)
Northern California (733)
Obesity (223)
Opinion (174)
Patents (79)
People (33060)
Pharmaceutical (78)
Phase I (13086)
Phase II (17754)
Phase III (14286)
Pipeline (311)
Policy (73)
Postmarket research (1614)
Preclinical (4594)
Radiopharmaceuticals (156)
Rare diseases (155)
Real estate (3185)
Regulatory (12198)
Research institute (824)
Resumes & cover letters (141)
Southern California (671)
Startups (2014)
United States (6674)
Vaccines (227)
Weight loss (189)
Date
Today (56)
Last 7 days (354)
Last 30 days (1462)
Last 365 days (17774)
2024 (17260)
2023 (19686)
2022 (25925)
2021 (26703)
2020 (24983)
2019 (20203)
2018 (15696)
2017 (17289)
2016 (16264)
2015 (18855)
2014 (14822)
2013 (12581)
2012 (13522)
2011 (13866)
2010 (12756)
Location
Africa (421)
Asia (24565)
Australia (3167)
California (1652)
Canada (807)
China (171)
Colorado (70)
Connecticut (67)
Europe (50714)
Florida (239)
Illinois (164)
Indiana (123)
Japan (62)
Maryland (242)
Massachusetts (1388)
Minnesota (96)
New Jersey (642)
New York (471)
North Carolina (372)
Northern California (733)
Ohio (64)
Pennsylvania (391)
South America (613)
Southern California (671)
Texas (228)
Washington State (153)
329,360 Results for "circle pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors
Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CID-078, a first-and-only-in-class cyclin A/B RxL inhibitor.
July 1, 2024
·
4 min read
Press Releases
Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024
December 9, 2024
·
2 min read
Press Releases
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment
October 9, 2024
·
4 min read
Press Releases
Circle Pharma Expands Leadership Team to Drive the Development of Its Pipeline of Oral Macrocycle Therapies
September 16, 2024
·
3 min read
News
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
October 23, 2024
·
2 min read
Press Releases
Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors
October 15, 2024
·
3 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Biotech Bay
Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023, in Boston, MA.
October 9, 2023
·
2 min read
Business
The Biggest Pharma Share Moves of the Year So Far
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share price. Other companies have not been so lucky.
November 27, 2024
·
9 min read
·
Annalee Armstrong
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
1 of 32,936
Next
